New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:39 EDTSGYPSynergy Pharmaceuticals price target raised to $13 from $7 at Cantor
Cantor increased its target on Synergy after the company reported results from a Phase III trial of its chronic constipation treatment, plecanatide, that the firm views as positive. The firm increased its E.U. and Japanese sales estimates for the drug, and it sees the company as a takeover target. Cantor believes that Synergy has multiple upcoming positive catalysts and it maintains a Buy rating.
News For SGYP From The Last 14 Days
Check below for free stories on SGYP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
09:10 EDTSGYPSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Synergy Pharmaceuticals' (SGYP) Plecanatide for Irritable Bowel Disease with constipation on an Analyst/Industry conference call to be held on April 17 at 11 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use